Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.34 USD | -0.68% | -3.30% | +48.78% |
May. 14 | Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 30 | North American Morning Briefing : More Earnings -2- | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 1.01M | Capitalization | 228M |
---|---|---|---|---|---|
Net income 2024 * | -76M | Net income 2025 * | -103M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 226 x |
P/E ratio 2024 * |
-3.04
x | P/E ratio 2025 * |
-2.75
x | Employees | 60 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.72% |
1 day | +1.23% | ||
1 week | -1.47% | ||
Current month | -4.27% | ||
1 month | -22.94% | ||
3 months | +49.60% | ||
6 months | +37.11% | ||
Current year | +50.20% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 18-03-31 | |
Kristina Masson
FOU | Founder | 44 | 18-02-28 |
Director of Finance/CFO | 53 | 22-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 55 | Feb. 07 | |
Sharon Shacham
BRD | Director/Board Member | 53 | 20-09-30 |
Chief Executive Officer | 62 | 18-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +4.32% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 7.32 | -0.95% | 48 687 |
24-06-05 | 7.39 | +1.09% | 57,080 |
24-06-04 | 7.31 | -5.06% | 172,620 |
24-06-03 | 7.7 | -0.26% | 121,199 |
24-05-31 | 7.72 | +1.98% | 127,119 |
Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+50.20% | 228M | |
+55.70% | 59.34B | |
+43.06% | 40.24B | |
-5.39% | 39.88B | |
-5.56% | 28.55B | |
+16.46% | 27.26B | |
-20.56% | 19.23B | |
+33.03% | 12.61B | |
+25.85% | 12.28B | |
+2.72% | 12.49B |
- Stock Market
- Equities
- ACRV Stock